HELP PEOPLE WITH CANCER
LIVE LONGER AND BETTER
1
MORE3D Medicines, Inc. is a clinical-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated next-generation immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both next-generation biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.
In February, 2021, the construction of 3D Medicines’ R&D and Manufacturing Center started in Xuzhou, Jiangsu.
Candidate Molecule
Target/
Mechanism
Rights
Preclinical
IND
Phase I
Phase II
Phase Ⅲ
NDA
Marketing
Candidate
Molecule
Target/
Mechanism
Rights
Preclinical
IND
Phase I
Phase Ⅱ
Phase Ⅲ
NDA
Marketing
Pan-cancer (>15 solid tumors including CRC, GC) with MSI-H/dMMR, mono, single-arm, ORR, 2L/3L
BTC, combo with chemo vs. chemo, randomized, OS, 1L
SC, mono, single-arm, ORR, 2L
NSCLC, combo, 1L
NSCLC, combo, 2L
GC, combo, 1L/2L
TMB-H, mono, single-arm, 2L/3L
EC, single-arm, combo with lenvatinib, 2L
HCC, combo with VEGF inhibitor, 1L/2L
RCC, combo with VEGF inhibitor, 1L/2L
NSCLC/OC/Kidney cancer/Pancreatic cancer
OC/Kidney cancer/Bladder cancer
"With the increasing incidence of cancer, cancer has become one of the major public health problems facing mankind; it not only poses a major threat to human health, but also causes a serious burden to economic and social development.
With commitment to the R&D and commercialization of a next-generation of innovative immuno-oncology drugs, 3D Medicines hopes to provide cancer patients across the globe with more effective, more accessible, and more convenient options of next-generation immuno-oncology drugs, thus helping them to live longer and better."
-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines Inc.
News
March 2, 2021 – 3D Medicines Inc. announced the appointment of Shen Xiao, M.D., Ph.D., as Chief Strategy Officer. He would be responsible for tasks including strategic innovation, competitive positioning and business model establishment for the company, he would provide support for the Chief Executive Officer on strategy planning and execution, and be in charge of the Regulatory Affairs Department. Shen Xiao, M.D., Ph.D., would report to John Gong, M.D., Ph.D., Chairman and Chief Executive Officer of 3D Medicines.
2021-03
02
News
February 26, 2021 – the construction of 3D Medicines’ R&D and Manufacturing Center was officially started, which was announced at the Xuzhou venue of the Joint Groundbreaking Ceremony of Jiangsu Province, as one of the 2021 Key Projects in Jiangsu.
2021-02
26
News
January 29, 2021 – 3D Medicines Inc. announced that the National Medical Products Administration (NMPA) has granted the IND approval for 3D011, a Class 1 innovative drug self-developed by 3D Medicines for the treatment of advanced solid tumors.
2021-01
29